BNT163

What it is

BNT163 is BioNTech’s prophylactic herpes vaccine candidate — one designed to prevent infection rather than treat an existing one. Its stated goal is to prevent the genital lesions caused by HSV-2, and potentially HSV-1.

It is an mRNA vaccine: it delivers genetic instructions that prompt the body’s cells to make selected viral proteins so the immune system learns to recognize them. It is a trivalent vaccine, encoding three HSV-2 glycoproteins (gC2, gD2, and gE2), with the aim of blocking the virus from entering and spreading between cells and of countering some of the ways the virus evades immune responses. BNT163 is the clinical form of the trivalent mRNA approach developed at the University of Pennsylvania and licensed to BioNTech — see Trivalent gC2/gD2/gE2 mRNA (UPenn) for the underlying preclinical science.

Where it stands

BNT163 is in a first-in-human Phase 1 trial (NCT05432583), a dose-escalation study evaluating safety, tolerability, and immune responses (including neutralizing antibodies) in healthy adults aged 18–55. The trial began in December 2022. Its status on ClinicalTrials.gov is Active, not recruiting, with estimated primary completion in October 2026.

A Phase 1 study of this kind is designed to answer whether the vaccine is safe and whether it triggers an immune response — not whether it prevents herpes. No efficacy data have been published. As of the date above, this is the only HSV vaccine from a large biopharmaceutical company still in active clinical development.